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Abstract
Background: Enhanced expression of the purinergic P2X7 receptor (P2X7R) occurs in several neuroinflammatory
conditions where increased microglial activation is a co-existing feature. P2X7 receptors can function either as a
cation channel or, upon continued stimulation, a large pore. P2X7R-over-expression alone is sufficient to drive
microglial activation and proliferation in a process that is P2X7R pore dependent, although the biological signaling
pathway through which this occurs remains unclear. Once activated, microglia are known to release a number of
bioactive substances that include the proinflammatory cytokine interleukin-1β (IL-1β). Previous studies have linked
P2X7R stimulation to the processing and release of IL-1β, but whether the channel or pore state of P2X7R is
predominant in driving IL-1β release is unknown and is a major aim of this study. In addition, we will determine
whether IL-1β has trophic effects on surrounding microglia.
Methods: Electron microscopy and immunohistochemistry were used to delineate the sub-cellular localization of
P2X7R and IL-1β in primary hippocampal rat cultures. FM1-43 fluorescent dye and confocal microscopy were used
to quantify vesicular exocytosis from microglia expressing the pore-forming P2X7R versus a non-pore-forming point
mutant, P2X7RG345Y. IL-1β in culture was quantified with an enzyme-linked immunosorbent assay (ELISA). IL-1β
intracellular processing was blocked with inhibition of caspase 1 (with a synthetic peptide antagonist), and its
extracellular form was neutralized with an IL-1β neutralizing antibody. Microglial activation and proliferation was
quantified immunohistochemically with confocal microscopy.
Results: P2X7R and IL-1β were co-localized in lysosomes. Vesicular exocytosis was higher in microglia expressing
the pore-forming P2X7R compared to those expressing the non-pore-forming mutant. There was increased IL-1β in
cultures expressing the pore-forming P2X7R, and this proinflammatory cytokine was found to mediate the trophic
effects of P2X7R pore in microglia. Inhibition of IL-1β production and function resulted in a significant decrease in
P2X7R-mediated microglial activation and proliferation.
Conclusions: IL-1β is a mediator of microglial activation and proliferation, and its release/production is P2X7R pore
dependent. Blockade of P2X7R pore could serve as a therapeutic target in alleviating the degree of inflammation
seen in neurodegenerative and neoplastic conditions.
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Background
The pathogenesis of a number of diseases such as Alzhei-
mer’s, Parkinson’s, multiple sclerosis, and human gliomas
are thought to be a result of chronic neuroinflammatory
processes. Microglial cells that exhibit specialized immune
characteristics in the central nervous system play a crucial
role in neuroinflammation. In a healthy CNS environ-
ment, microglia exhibit a quiescent morphology. However,
under pathological conditions and in the setting on neuro-
inflammation, they undergo a process known as micro-
gliosis. In this situation, microglia become activated with
an enlarged soma, and acquisition of lamellapodia. They
up-regulate the synthesis of a number of bioactive sub-
stances such as cytokines. The identity, amount, and tem-
poral expression profile of these cytokines determines if
the neuroinflammatory process are neuroprotective or ul-
timately lead to neurodegeneration [1].
Interleukin-1β (IL-1β) is a proinflammatory cytokine
released by activated macrophages and microglia. There
are numerous reports highlighting that the release of IL-
1β from immunological cells is dependent on the activity
of P2X7 receptor (P2X7R) [2–12], a purinergic receptor
that is expressed in cells of hemopoeitic and immuno-
logical origin (including monocytes, macrophages, and
microglia). The stimulation of P2X7R allows a significant
efflux of K+, which favors the formation of the active
form of caspase 1 [13], leading to production of mature
IL-1β. P2X7R can therefore modulate inflammation by
influencing cytokine production.
An enigmatic feature of P2X7R is its dual conductance
states. Brief stimulation of P2X7R with agonists such as
ATP or 2′3′-O-(4-benzoylbenzoyl)-ATP (BzATP) leads to
opening of the P2X7R channel permeable to small cations.
However, sustained stimulation leads to formation of a
P2X7R pore permeable to moieties of up to 900 Da. The
physiological basis and biological role of P2X7R pore
formation is currently unresolved. Interestingly, polymor-
phisms in P2X7R are reported to alter cytokine production.
One such polymorphism, Glu496Ala, leads to loss of func-
tion of P2X7R [14], with reduced ATP-stimulated K+ efflux
and delayed release of IL-1β [9]. While P2X7R is clearly
important in the production/release of IL-1β, the relative
contributions of channel or pore conductance and the
exact mode of release of the cytokine are unknown. IL-1β
does not contain signal sequence for compartmentalization
within the Golgi or the classical secretory pathway; there-
fore, pro-IL-1β accumulates within the cytosol [15]. IL-1β
is thought by some to be released via simple budding of
the plasma membrane into small membrane-delimited
microvesicles [16], while others have reported release via
small vesicles named exosomes (derived from exocytosis of
multivesicular bodies) [17] or to be simply subsequent to
cell death [15]. Release via lysosomal vesicular exocytosis
has also been suggested [18].
P2X7R over-expression is sufficient to drive microglial
activation and proliferation, trophic responses that were
shown to be dependent on the pore activity of P2X7R
[19, 20]. Similarly, in human glioma cultures, P2X7R
over-expression in glioma-associated microglia and sub-
sequent inhibition of P2X7R were sufficient to reduce
glioma cell number [21]. There is an established link be-
tween P2X7R function and the release/production of the
proinflammatory mediator IL-1β [2, 4, 5, 16]. Here, we
reveal that IL-1β release is P2X7R pore dependent and
that the blockade of the P2X7R pore could serve as a
therapeutic option for alleviation of inflammation.
Methods
DNA constructs and site-directed mutagenesis.
Two enhanced green fluorescent protein (EGFP) fusion
constructs used in this study for transfection of primary
hippocampal astrocyte-microglia mixed cultures were as
follows: P2X7R-EGFP where the wild type rat P2X7R (ac-
cession number: X95882) was fused to the N terminus of
EGFP and P2X7RG345Y-EGFP where a point mutant of
P2X7R was fused to the N terminus of EGFP as previously
described [20]. This mutant, P2X7RG345Y-EGFP, was pro-
duced by targeting the glycine at position 345 in the rat
P2X7R for substitution with tyrosine using a Quick-
Change Site-Directed Mutagenesis Kit (Stratagene) with
the following primers:
Forward: 5′C ACC CTG TCC TAT TTC TAT TTG
GCC ACC GTG TG
Reverse: 5′ CA CAC GGT GGC CAA ATA GAA ATA
GGA CAG GGT G
Base changes introducing the G345 to Y mutation are
in bold type and underlined. All constructs were
expressed under the influence of CMV promoter.
Primary hippocampal neuron-glia mixed cultures
Protocols for handling animals were reviewed and ap-
proved by the Animal Ethics Committee at The Univer-
sity of Melbourne, Australia. Primary hippocampal
neuron-glia mixed cultures were prepared from P2-5
Sprague-Dawley rats as described previously [22]. Briefly,
the animals were anesthetized by halothane inhalation,
the brains were removed, and the hippocampi were dis-
sected out and finely chopped. The hippocampal pieces
were placed in an enzyme solution containing papain
(200 units; Sigma-Aldrich) for 35 min at 37 °C. The hip-
pocampal tissue was washed three times to remove all
traces of papain, and the mixture was triturated to ob-
tain a single cell suspension. The cells were plated into
12-well plates containing 18-mm poly-D-lysine (Sigma)
coated coverslips (SDR Clinical Technology) at a density
of 1.8 × 105 cells/well. The cultures were maintained in
Minimum Essential Medium (Gibco, Invitrogen) with
the following supplements: 1 mM glucose, penicillin-
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streptomycin (5000 units/mL), 10 % heat inactivated
fetal bovine serum (Gibco, Invitrogen), MITO+™ Serum
Extender (Becton Dickinson), and 2 mM L-glutamine
(Gibco, Invitrogen). The cells were cultured at 37 °C in a
humidified incubator of 5 % CO2/95 % O2. Untrans-
fected cultures contained ~48 % astrocytes and ~50 %
microglia as assessed by immunohistochemistry using
antibodies against glial fibrillary acidic protein (GFAP)
and isolectin GS-IB4, respectively.
Microglia-enriched cultures
Initially, neuron-glia mixed cultures were prepared in
75 cm2 flasks (JRH Biosciences). One animal was used
per 75 cm2 flask. After 14 days, the flasks of mixed
neuron-glia cultures were shaken (Economy Orbital
Mixer, U-lab) at 150 rpm for 4 h at 37 °C, to dislodge
microglia loosely attached to underlying astrocytes. The
medium containing microglia was then aspirated and
centrifuged at 1000 rpm for 5 min. The pellet of micro-
glia was re-suspended in supplemented culture medium
and placed in 12-well plates containing poly-D-lysine-
coated coverslips. One 75 cm2 flask of mixed cultures
was used for preparing four coverlips (wells) of a 12-well
culture plate. There were 3.1 × 104 microglia/coverslip at
24 h post-harvest. The media was changed once a week,
and the cells were maintained in the incubator for fur-
ther 1 week before use in the experiments. Purity was
assessed by labeling with the microglial maker, isolectin
GS-IB4, which identified 94 % of cells as microglia.
Enzyme-linked immunosorbent assay (ELISA) experi-
ments were conducted using microglia-enriched cultures
to quantify the amount of IL-1β in culture.
Transfection
The exogenous plasmid DNA constructs, P2X7R-EGFP
or P2X7RG345Y-EGFP, were individually introduced into
cultured cells using a modified calcium phosphate trans-
fection technique [23], with the aid of a CalPhos™ Mam-
malian Transfection Kit (Becton Dickinson Biosciences)
according to the manufacturer’s protocols. The DNA
concentration used was 2 μg/well of a 12-well culture
plate (1.8 × 105 cells/well). The expression of the exogen-
ous constructs was monitored with an Olympus IX 81
fluorescence microscope 72 h post-transfection. This
time was sufficient for the folding and trafficking, which
are identical for each receptor type, and for the diver-
gence of downstream effects of each exogenous P2X7R.
The transfection efficiency was 20 %.
Immunohistochemistry
At 72 h post-transfection, neuron-glia mixed cultures
were fixed for 15 min in a 4 % paraformaldehyde solu-
tion at room temperature. After fixation, the cells were
washed once with phosphate-buffered saline (PBS), and
non-specific protein binding sites were blocked with 2 %
bovine serum albumin (Sigma) for 45 min at 37 °C. The
following primary antibodies were used: mouse anti-GFP
(final dilution, 1:200; Molecular Probes), anti-LAMP1
primary antibody (final dilution of 1:200; Abcam), isolec-
tin GS-IB4 from Griffonia simplicifolia, Alexa Fluor® 594
conjugate (final dilution of 1:100; Molecular Probes),
anti-IL-1β (MAB501; final dilution, 1:100; Abcam), and
OX-6 (anti-MHC II) (final dilution, 1:100; BD Pharmin-
gen). Primary antibodies were made up in PBS, with 1 %
Triton X-100 for permeabilization, and were incubated
overnight at 4 °C. After three 5-min washes in PBS, the
sections were incubated with the relevant secondary
antibodies: Alexa Fluor® 488 (final dilution, 1:200; Mo-
lecular Probes) or Texas Red® X (final dilution, 1:200;
Molecular Probes). All secondary antibodies were incu-
bated overnight at 4 °C. After three 5-min washes in
PBS, the samples were mounted with DAKO Fluorescent
Mounting Medium. No staining was detected in the
absence of the primary or secondary antibodies. Some
preparations were counter-labeled with DAPI nuclear
stain (5 μM; Molecular Probes).
Confocal microscopy
Seventy-two hours post-transfection, primary mixed cul-
tures were viewed with an Olympus IX-81 fluorescence
microscope equipped with a DG4 light source. Images
were acquired with a 40× LucPlanFI Olympus (N.A. 0.6)
air objective. For most experiments, the samples were
simultaneously stained with two or three fluorescent
probes, with dual or triple emission achieved through ap-
propriately selected emission filters. Images were analyzed
using MetaMorph (Universal Imaging Corporation®) soft-
ware for assessment of microglial activation and prolifera-
tion. For live cell imaging, the cells were bathed in HEPES
buffer (mM: NaCl 135, KCl 5, HEPES 10, Glucose 10,
CaCl2 1, MgCl2 pH 7.4) at room temperature (~25 °C).
Electron microscopy
The primary hippocampal neuron-glia mixed cultures
were seeded onto thermanox coverslips (ProScitech).
Seven days post culture, the cells were transfected with
various DNA constructs. The transfected coverslips were
fixed with 4 % paraformaldehyde and 0.1 % glutaraldehyde
for 10 min at room temperature and transferred to the
EM facility (The University of Melbourne) for embedding
and grid sectioning (thin sections). Thin cryosections were
prepared from glutaraldehyde and/or paraformaldehyde-
fixed tissue after infusion with 2.3 M sucrose. The sections
were then composed on carbon-coated nickel and picked
up on a solid layer of 2 % gelatin in buffer. The grids were
then prepared for immunohistochemistry.
On a sheet of wax (paraffin) for each grid, a ~0.5-mL
drop of blocking buffer (1 % BSA made in PBS) was
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placed. With fine forceps, the grids were individually po-
sitioned on top of the buffer (cells facing up) floating in
the droplet. Non-specific binding sites were blocked for
10 min at room temperature. The grids were then trans-
ferred to drops of primary antibody (1:50 final dilution,
anti-GFP antibody; Molecular Probes). The primary anti-
body was made up of PBS with 0.1 % Tween 20
(Amresco). The grids were incubated with primary anti-
body for 24 h at 4 °C, washed (three times) by gently
transferring them to drops of washing buffer (sodium
cacodylate trihydrate; Sigma), and then incubated for 2 h
with drops of secondary antibody, anti-mouse IgG
(whole molecule) gold conjugate, 10 nm (Sigma), diluted
just before use to a concentration of 1:50. The grids
were placed in a washing buffer (2 × 10 min washes),
and the cells post fixed in 2 % glutaraldehyde in PBS
and then washed with cacodylate buffer, for 3 × 2 min.
The grids were returned to the EM facility, stained
with uranyl acetate in veronal buffer (pH 6.4) for
15 min, washed in water for 3 × 2 min, and dehydrated
through 40 %, 75 %, 95 %, and 2 × 100 % ethanol for
2 min each. They were then left in 50/50 ethanol/LR
(London resin) white for 10 min, then left in 100 % LR
white for 2 × 10 min, and then sandwiched between
Whatman filter papers with light pressure applied to re-
move residual liquid. After 1–2 h in an oven at 60 °C
grids were counterstained with conventional uranyl acet-
ate and lead citrate. The cells were viewed with an elec-
tron microscope with a minimum ×2000 magnification.
Negative controls without primary antibody were gener-
ated for all experiments, and no signal was obtained.
Assessment of microglial activation
Microglial activation was assessed using morphological
and immunohistochemical criteria as previously de-
scribed [20]. Before analysis of activation, microglia were
classified into two groups. Cells with an oval cell body
containing a small volume of cytoplasm and long, thin,
delicate, and radially branched processes were classified
as ramified microglia [24]. Activated microglia were de-
fined as having an enlarged soma (width greater or equal
to 30 μm) [25, 26] and a broad-flattened appearance
with the common presence of several lamellapodia [27].
This morphological classification was confirmed immu-
nohistochemically by the use of microglial specific
markers isolectin GS-IB4 and CD-11b.
Assessment of microglial proliferation
We used isolectin GS-IB4 as previously described [28],
to quantify microglial proliferation. The transfected cells
were identified with anti-GFP and a secondary Alexa
Fluor® 488 antibodies. Microglia were selectively identi-
fied with isolectin GS-IB4 staining, and all nuclei were
stained with DAPI (Molecular Probes). Images were
analyzed using MetaMorph (Universal Imaging Corpor-
ation®) software for assessment of proliferation.
Assessment of microglial exocytosis- FM1-43 experiments
Shedding of vesicular contents (exocytosis) from micro-
glia expressing the pore- or non-pore-forming P2X7R
was visualized by labeling the cells with the membrane
permeant dye FM1-43 and measuring the changes in cell
surface fluorescence upon P2X7R stimulation. ATP and
BzATP were used to stimulate P2X7R. As well as label-
ing of vesicles and vesicular contents, the uptake of the
styryl (FM) dyes is generally utilized in the study of dy-
namics of vesicular release (endo- and exocytosis) [18].
FM1-43 is known to stain lysosomes and reveal lyso-
somal vesicular recycling [29]. Upon vesicular release,
the cell surface FM1-43 fluorescence is expected to in-
crease as the intracellular vesicle that is docking just in-
side the cell fuses with the cell membrane [30].
Thereafter, the membrane fluorescence is expected to
transiently decrease as the contents are released.
The x,y coordinates of activated microglia expressing
P2X7R-EGFP or P2X7RG345Y-GFP were recorded for
later imaging and all cells were loaded with 5 μM of
FM1-43 for 5 min while the cells were bathed in PBS.
Then, the cells were washed with BPS and incubated in
HEPES buffer.
Fusion events were monitored as a time series of cell and
the plasma membrane fluorescence. The temporal distribu-
tion of exocytosis events was obtained by defining regions
of interest (ROI) of the cell surface and monitoring
changes in membrane fluorescence using “TimeSeries”
(LSM510 META software). All fluorescence values were
corrected for background fluorescence levels.
Media exchange experiments
At 72 h post-transfection, the supernatant derived from
cultures expressing P2X7R-EGFP or P2X7RG345Y-EGFP
was transferred to untransfected 7-day-old primary hip-
pocampal cultures, and the cultures were subsequently
kept at 37 °C in a humidified incubator of 5 % CO2/95 %
O2 for a further 72 h. Thereafter, the cells were fixed in
4 % paraformaldehyde (10 min) and processed for im-
munohistochemistry with isolectin GS-IB4 to determine
the number of microglia and DAPI nuclear stain to
quantify the total number of cells.
IL-1β enzyme linked immunosorbent assay (ELISA)
IL-1β produced in the hippocampal microglia-enriched
cultures expressing P2X7R-EGFP or P2X7RG345Y-EGFP
was quantified with the aid of a Quantikine IL-1β ELISA
kit (R&D Systems), according to the manufacturer’s pro-
tocols. Briefly, 72 h post-transfection, the cultures ex-
pressing P2X7R-EGFP or P2X7RG345Y-EGFP were
exposed to BzATP (100 μM), a specific agonist of
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P2X7R, for 30 min. At this time point, detectable
amounts of ATP-induced IL-1β release have been previ-
ously reported [7]. Supernatants were collected and cen-
trifuged at 2000 rpm for 3 min to pellet cellular debris.
Triton X-100 (1 %) was added to the purified superna-
tants and gently mixed to dislodge IL-1β from the shed
microvesicles [16] for assay by ELISA.
Caspase 1 inhibition experiments
Primary hippocampal cultures expressing P2X7R-EGFP or
P2X7RG345Y-EGFP at 24 h post-transfection were exposed
to N-Acetyl-TRP-GLU-His-Asp-AL (0.67 mg/mL; Sigma-
Aldrich), a potent antagonist of ICE (caspase 1) [31, 32].
The inhibitor was left in culture from 24 to 72 h. The 24-h
time point allows sufficient time for expression of the ex-
ogenous constructs (unpublished findings). At 72 h post-
transfection (allowing sufficient time for downstream sig-
naling cascades to develop), the cultures were fixed and
processed for immunohistochemistry to measure the
degree microglial activation and proliferation.
IL-1β neutralization experiments
The activity of the mature (extracellular) IL-1β was
blocked with a specific IL-1β neutralizing antibody
(R&D Systems). At 24 h post-transfection, the cultures
expressing P2X7R-EGFP or P2X7RG345Y-EGFP were
treated with a neutralizing antibody (1:50), and at 72 h
post-transfection, the cultures were processed for immu-
nohistochemistry and imaging to quantify microglial ac-
tivation and proliferation.
Results
P2X7R-activated microglia exhibited “nodular structures”
containing intraluminal vesicles which expressed P2X7R
P2X7R transfection is sufficient to drive microglial activa-
tion and proliferation [20]. Primary hippocampal cultures
transfected with P2X7-EGFP showed that the cells express-
ing the exogenous construct co-localized with that of the
microglial marker, isolectin GS-IB4 (Fig. 1a) and another
maker of activated microglia OX-6 (MHC II) (Fig. 1b). The
cells expressing P2X7-EGFP did not co-localize with that
of an astrocytic marker, GFAP (Fig. 1b, c).
“Beaded” structures outside the cell that emanated
from “nodular” outpouchings of the cell cytoplasm were
evident in microglia (isolectin GS-IB4 positive) express-
ing exogenous P2X7R (Fig. 2a). Figures 2b, c shows high
concentrations of P2X7R expression in the “nodular
structures” of activated microglia (Fig. 2b, c).
Electron microscopy revealed that the “nodular struc-
tures” contained multiple round intraluminal vesicles
ranging in size from 0.1 to 0.2 μm docked near the
plasma membrane (Fig. 3a). Immuno-gold revealed that
P2X7R receptor expressed on the membrane of vesicles
as well as on nearby plasma membrane (Fig. 3b, c).
Immunohistochemical analysis indicates that sub-
plasma membrane vesicles expressing P2X7R also
expressed IL-1β (Fig. 3d). The expression of IL-1β co-
localized with a marker of lysosomes, LAMP-1
(Fig. 3e, f ).
Microglia expressing the pore-forming P2X7R showed a
higher degree of vesicular exocytosis
Exocytosis was measured with FM1-43, a cell permeant
fluorescent dye that loads lysosomal vesicles [29]. Figure 4a
shows an activated microglia expressing wild-type P2X7R
and stained with FM1-43. ATP caused an initial increase
in plasma membrane fluorescence (indicating fusion of
sub-plasmalemmal vesicles with the cell surface) and sub-
sequent decrease in fluorescence (indicating extracellular
release of vesicular contents) (Fig. 4b). The change in
membrane fluorescence in response to ATP (3 mM) was
significantly higher in cells expressing P2X7R-EGFP com-
pared to those expressing P2X7RG345Y-EGFP (Fig. 4c),
indicating that the cells expressing the pore-forming
P2X7R were undergoing more exocytosis (release events/
unit time). To confirm that the response was P2X7R spe-
cific, the experiment was repeated using BzATP (specific
P2X7R agonist [33]) and oxATP (specific P2X7R antagon-
ist, [34]). Figure 5a shows that when stimulated with
BzATP, vesicles of ~200 μm diameter appeared on the sur-
face of the cell followed by subsequent “release events”
(see Additional file 1 for detailed images of the experiment
in real time). The fused puncta often faded within 100–
180 s. In response to BzATP, there was a significantly
more vesicular exocytosis from microglia expressing the
pore-forming wild-type P2X7R than those expressing the
non-pore-forming mutant (G345Y) (Fig. 5b, c). This fur-
ther confirmed that P2X7R pore is involved in exocytosis
events in microglia and that the response is P2X7R spe-
cific, as it was blocked with oxATP.
Media derived from primary hippocampal cultures
expressing the pore-forming P2X7R contain a factor that
is trophic to microglia
Media from untransfected hippocampal cultures were
replaced with the supernatants from cultures expressing
either wild-type or mutant non-pore-forming P2X7R
(P2X7RG345Y-EGFP). The absolute number and the
proportion of microglia in culture were increased by
supernatant derived from cultures expressing the wild-
type construct compared to the mutant (Fig. 6a–c). This
suggested that P2X7R pore-mediated biological “fac-
tor(s)” contained in the media were capable of driving
microglial proliferation in untransfected cultures.
In response to BzATP (100 μM) stimulation, the extra-
cellular medium from cultures expressing the wild-type
P2X7R-EGFP contained a significantly higher amount of
IL-1β, than that from cultures expressing non-pore-
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forming P2X7RG345Y-EGFP (Fig. 6d). If IL-1β is a po-
tential facilitator of the P2X7R-mediated trophic effects
on microglia, we would expect that inhibiting the action,
or reducing the levels, of IL-1β would reduce the level of
P2X7R-mediated microglial activation and proliferation
of microglia.
Microglial activation is inhibited following the blockade
of IL-1β processing to its active form
Processing of IL-1β to its active form was inhibited by
blocking the intracellular actions of caspase 1 with a
specific antagonist (N-Acetyl-TRP-GLU-His-Asp-AL).
As a result, the total number of cells (Fig. 7c), the
number of activated microglia expressing P2X7R
(Fig. 7d), and the number of microglia (Fig. 7e) were all
reduced. These results highlight the production of the
active IL-1B to be an important step in P2X7R-mediated
activation of microglia.
Microglial activation and proliferation is reduced by
neutralization of extracellular IL-1β
When the potential effects of the extracellular, active
form of IL-1β were abolished, microglial activation and
proliferation were markedly reduced. Addition of an IL-
1β neutralizing antibody to cultures expressing exogen-
ous wild-type P2X7R caused significant reduction in the
Fig. 1 a In P2X7R-EGFP-transfected primary hippocampal cultures, the transfected cells co-localized with microglia marker isolectin GS-IB4 (red: microglial
marker—isolectin GS-IB4, green: P2X7-EGFP). b Also, in P2X7R-EGFP-transfected primary hippocampal cultures, the transfected cells co-localized with
another microglia marker OX-6 anti-MHC II (red: microglial marker—OX-6, green: P2X7-EGFP). c, d No co-localization was observed between cells expressing
P2X7R-EGFP and astrocytes (green: P2X7R-EGFP, red: GFAP—astrocytic marker). Scale bar: 5 μm
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total number of cells (Fig. 7f ), the number of activated
microglia expressing exogenous P2X7R (Fig. 7g), and the
number of microglia (Fig. 7h).
Discussion
Here, we reveal that microglial vesicles adjacent to
the plasma membrane co-express P2X7R and IL-1β
and are likely to be of the lysosomal family of vesi-
cles. Lysosomal vesicular exocytosis was more pro-
nounced in activated microglia expressing wild-type
P2X7R as opposed to those expressing a non-pore-
forming mutant (P2X7G345Y). Cultures expressing
wild-type P2X7R contained higher quantities of the
extracellular (released) form of IL-1β than those ex-
pressing the non-pore-forming mutant. We also reveal
that IL-1β is a key cytokine mediating the trophic ef-
fects of the P2X7R pore in microglia, as inhibition or
neutralization of IL-1β resulted in significant reduc-
tion in P2X7R pore-driven microglia activation and
proliferation. These findings highlight an important
role for P2X7R pore formation and consequent pro-
duction and release of IL-1β, indicating the critical
role that is played by P2X7R pore formation in the
hierarchy of neuroinflammation.
Activated microglia contain sub-plasma membrane ves-
icles that express IL-1β and P2X7R and these vesicles
are of lysosomal origin
In this study, we showed that activated microglia dis-
played “nodular structures” as outpouchings of the cell
cytoplasm containing discrete vesicles ranging 100–
200 μm in diameter. These vesicles expressed P2X7R,
IL-1β, and the lysosomal maker LAMP-1.
Fig. 2 Primary hippocampal cultures expressing exogenous P2X7R exhibited nodular structures as outpouchings of the cell cytoplasm from
which emanated a highly organized array of what appeared to be vesicles. a Cultures expressing P2X7R stained with microglial marker isolectin
GS-IB4 showed nodular structures (arrow head) from which projected “beaded” structures to the outside of the cell (arrows). Inset shows a
higher resolution of the “beaded” structures. b, c Examples of activated microglia expressing exogenous P2X7R-EGFP. As can be noted
“nodular” outpouchings of the cell are once again evident with fluorescent “beaded” structures outside the cell. Scale bar: as indicated in
the figures
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The proposed mechanisms of release of IL-1β in-
clude (i) exocytosis of secretory lysosomes, (ii) release
of membrane spanning microvesicles derived from
plasma membrane blebs, (iii) release of membrane-
delimited exosomes derived from multivesicular bod-
ies formed by invagination of endosomes, (iv) exocyt-
osis of autophagosomes, and (v) direct release to the
extracellular environment subsequent to cell death
[15]. Our data support the lysosomal mode of release.
Lysosomes were previously considered as end organ-
elles in protein degradation, but recent studies have
shown that lysosomes may also play roles in cellular
signal transduction and secretion of signaling
molecules [35, 36]. In cells of hemopoietic origin such
as microglia, the lysosome can act as a secretory or-
ganelle [35, 36]. Previously it has been shown that
FM143 and AM143 label lysosomal vesicles (by co-
localizing with lysosomal markers LAMP1 and
cathepsin D), but not endosomes (no evidence of co-
localization with endosomal marker EAA1) [30]. Our
data, showing lysosomal localization of IL-1β and co-
expression with P2X7R, indicates that it is likely that
lysosomal exocytosis is involved in IL-1β release from
microglia.
Expression of vesicles containing bioactive sub-
stances and their calcium-induced exocytosis were
Fig. 3 a–c Electron micrographs of microglia from cultures expressing P2X7R-EGFP. As can be noted within the nodular structures, there resides
small vesicles ranging in size from 100 to 200 μm (arrows) (a) and there is expression of P2X7R within the membrane of these vesicles (b, c). Scale
bar 1 μm. d The vesicular structures expressing P2X7R were co-localized with expression of IL-1β. Green: anti-P2X7R antibody followed by Alexa
Fluor 488. Red: anti-IL-1β antibody with secondary anti-Texa Red X. Far right image shows co-localization of P2X7R and IL-1β. e–f the vesicular
structures expressing P2X7R also expressed LAMP-1 (marker of lysosomal vesicles). Green: anti P2X7R antibody followed by Alexa Fluor 488. Red:
LAMP 1 antibody with secondary anti-Texa Red X. Far right image shows co-localization of IL-1β in lysosomes
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long thought to be a property exclusive to neurons
and neuroendocrine cells. However, significant evi-
dence in the last 10 years indicates exocytosis of vari-
ous factors from glia, in a process now called
gliotransmission [37]. In astrocytes, FM1-43 only
labels lysosomes, calcium-dependent exocytosis of ly-
sosomes has been revealed by confocal microscopy
[29, 38], and it was proposed that the lysosome is the
major type of vesicle for calcium-regulated exocytosis.
Thus, we reveal that microglia are similarly compe-
tent in undergoing exocytosis, and the process is
P2X7R pore dependent.
The release of IL-1β is P2X7R pore dependent
In agreement with our findings, there are numerous prior
reports that the release of IL-1β is dependent on P2X7R
function [2, 5, 8, 10, 16, 39]. Grahames and colleagues re-
ported that exogenous application of ATP resulted in the
release of IL-1β from human monocytes, and the pharma-
cological profile was consistent with that of P2X7R stimu-
lation [7]. Similarly, macrophages derived from P2X7R
knockout mice did not release IL-1β in response to ATP
stimulation [8]. Moreover, oxATP, an irreversible antagon-
ist of both ion channel and pore conductances of P2X7R
[34] was found to abolish ATP-induced IL-1β release from
Fig. 4 Shedding of vesicular contents (exocytosis) from microglia expressing the pore or non-pore-forming P2X7R was visualized by labeling the
cells with the membrane permeant dye FM1-43 and measuring the changes in cell surface fluorescence upon P2X7R stimulation. ATP and BzATP
were used to stimulate P2X7R. a An activated microglia expressing the pore-forming P2X7R, which was then loaded with FM1-43. Red: FM1-43.
Green: P2X7R-EGF expression. Upon ATP stimulation, there appeared to be the presence of vesicular structures arising on the surface of the cell
(arrows) which were then released into the extracellular milieu. The images are from 0 to 3.5 min after stimulation with 3 mM of ATP. b The cell
membrane fluorescence increased with ATP stimulation (coinciding with fusing of the vesicular membrane with cell surface membrane). This was
then followed by a decreased in membrane fluorescence. Arrow indicates time of application of 3-mA ATP. c The change in membrane fluorescence
(measured in experiments conducted up to 25 min) in response to ATP (3 mM) was significantly higher in cells expressing P2X7R-EGFP (n = 13 cells
from 13 different rats) compared to those expressing P2X7RG345Y-EGFP (n = 12 cells from 12 different rats)
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human macrophages [4]. Mariathasan and colleagues de-
scribed a mechanism whereby P2X7R acted up-stream of
the inflammasome to ultimately lead to the production
and release of IL-1β [40].
In addition, P2X7R stimulation was also linked to the
activation of NF-kB [41], a factor whose activity is
thought to lead to enhanced transcription of IL-1β gene.
As the experimental conditions used in all of these stud-
ies would involve stimulation, or conversely, antagonism
of both ion channel and pore conductance, it is not
possible to distinguish whether P2X7R channel or pore
conductance was predominantly responsible for the pro-
duction and release of IL-1β. Although recognized for
its pro-death properties [5, 42–52], the contribution of
the P2X7R pore to trophic cellular effects was largely
unknown. Recently, we revealed that up-regulation of
the P2X7R pore lead to microglial activation and prolif-
eration [20] and now reveal IL-1β to be a key extracellu-
lar mediator of the trophic effects. Interestingly, Di
Virgilio and colleagues reported that amyloidβ peptide
(Aβ25–35) triggered increases in intracellular Ca
2+, IL-1β
release, and plasma membrane permeabilization in
microglia derived from wild-type but not P2X7R-
deficient mice [2]. However, the results of this study, al-
though consistent with activation of pore conductance,
did not distinguish the specific contributions of the
P2X7R pore and channel.
An attempt at this distinction between P2X7R channel
and pore activities was made with P2X7R truncation
mutants, where segments of the C terminus are removed
to produce a mutant receptor without the capacity to
form pores [53]. However, we have previously shown
with P2X7R truncation mutants that while the C
terminus is critical for P2X7R pore activity (the receptor
needing 95 % of its C terminus to retain its pore func-
tion), the majority of P2X7R C-terminal truncation
mutants suffer from altered folding, trafficking, and
many rather than reaching their final plasmalemmal des-
tination, aggregate in intracellular organelles [52]. In
addition, the C-terminal domain of P2X7R is imperative
in the interaction of the receptor with intracellular sig-
naling cascades [54]. By deleting these regions, one
would inevitably abolish the ability of the receptor to
participate in potentially important cellular signaling
Fig. 5 a An activated microglia expressing P2X7R-EGFP, subsequently loaded with FM1-43. When this cell was then stimulated with BzATP (100 μM),
vesicles of ~200-μm diameter appeared on the surface of the cell which was followed by subsequent “release events” (see Additional file 1 for detailed
images of the experiment in real time). The exocytosis was relatively fast to begin with, starting within 15 s of application of the agonist, reaching its
maximum within 90–120 s and continuing for a duration of 5 min. b Change in membrane fluorescence as a measure of vesicular exocytosis in FM-143-
loaded cells in response to 100 μM BzATP. Change in membrane fluorescence from cells expression wild-type P2X7R (P2X7R-EGF; red line) and loaded
with FM-143 as compared to those expressing the non-pore-forming mutant (P2X7RG345Y-EGFP; blue lines) as compared to those expressing wild-type
P2X7R (P2X7R-EGF) but pre-treated with oxATp (purple lines) (100 μM). c The sum of exocytosis was presented as change in membrane fluorescence. In
response to 100 μM BzATP, there was a significantly higher amount of vesicular exocytosis from microglia expressing the pore-forming wild-type P2X7R
(P2X7R-EGF) as compared to those expressing the non-pore-forming mutant (P2X7RG345Y-EGFP) or those expressing the wild-type P2X7R with prior
inhibition with P2X7R antagonist, oxATP (100 μM)
Monif et al. Journal of Neuroinflammation  (2016) 13:173 Page 10 of 15
cascades. In the current study, we used instead
P2X7RG345Y, a full-length, point mutant of P2X7R, with
normal trafficking and expression properties with intact
channel function but ablated pore-forming capacity [20]
to show that the release of IL-1β was P2X7R pore
dependent.
Our data indicates that the release of the cytokine is
likely via lysosomal exocytosis, rather than cell lysis as
suggested for macrophages [55], as P2X7R pore activity
enhances microglial proliferation with no evidence of
cytolysis [20]. In agreement, others have unequivocally
dissociated the P2X7R-induced release of IL-1β from cy-
tolysis [56] in human monocytes [57], human macro-
phages [4], and mouse peritoneal macrophages [3].
Li and colleagues found that pore dilation results from
time-dependent alterations in the concentration of intra-
cellular ions [58]. The P2X7R pore is unlikely to func-
tion as a transporter or conduit for the cytokine, due to
the difference in size of the pore (≤900 Da) and the im-
mature (34 kDa) and mature (17 kDa) forms of IL-1β
Fig. 6 Media derived from primary hippocampal cultures expressing the pore-forming P2X7R contain a factor trophic for microglia. a Representative
image of untransfected primary hippocampal cultures exposed for 72 h to the supernatant derived from cultures expressing P2X7R-EGFP. Red, isolectin
GS-IB4; blue, DAPI nuclear stain. Scale bar, 10 μm. b The percentage of microglia (isolectin GS-IB4-positive cells) over the total number of cells (DAPI-positive
cells) per imaging field was increased in cultures exposed to P2X7R-EGFP-derived supernatant compared to P2X7RG345Y-EGFP supernatant. c The absolute
number of microglia (isolectin GS-IB4-positive cells) per imaging field was increased in cultures exposed to P2X7R-EGFP-derived supernatant compared with
P2X7RG345Y-EGFP supernatant. Cell numbers were determined from 49 and 48 randomly selected fields (x–y dimensions: 230 × 230 μm), respectively, from
at least three independent experiments, 72 h post exposure to the supernatants. Data are mean ± SEM. d ELISA for IL-1β shows significantly higher levels
of the proinflammatory cytokine release in primary hippocampal cultures expressing P2X7R-EGFP (n= 6) than in those expressing P2X7RG345Y-EGFP (n=
6). The absorbance data were measured in duplicates. The results show mean ± SEM. *p< 0.05 (Student’s t test)
Monif et al. Journal of Neuroinflammation  (2016) 13:173 Page 11 of 15
[59]. P2X7R pore formation may instead lead to activa-
tion of intracellular signaling cascades such as MAPK or
Rho-effector kinase, or induction of NF-kB, ultimately
leading to transcription, as well as caspase 1-induced
processing and release of IL-1β via lysosomal exocytosis.
The trophic effects of P2X7R pore are mediated by IL-1β
Our findings are consistent with previous reports that
basal proliferation of microglia is stimulated by IL-1β or
tumor necrosis factor-α (TNF-α) [60]. The literature link-
ing microglial activation and excess IL-1β release, with the
pathogenesis of a number of neuroinflammatory condi-
tions is extensive [61, 62]. Of particular note are
observations that human IL-1 is elevated in cerebrospinal
fluid derived from patients with brain injury [63], and the
increased levels reported within brain lesions from
patients with Alzheimer’s disease, multiple sclerosis, and
HIV-associated dementia [64–67], and in CSF in
Parkinson’s disease and Creutzfeldt-Jakob disease [68, 69].
Once released, IL-1β in turn can exert autocrine ac-
tions on microglia, and paracrine actions on astro-
cytes [70]. IL-1β can cause the production of a
number of other proinflammatory bioactive substances
(nitric oxide and IL-6) from astrocytes and microglia
in culture [71, 72]. In turn, these substances have
been implicated in the propagation of a number of
CNS injuries and diseases [73].
Fig. 7 Inhibition of interleukin converting enzyme caspase 1 (with N-Acetyl-TRP-GLU-His-Asp-AL at 0.67 mg/mL) or neutralization of IL-1β activity
decreases microglial activation. Representative images from cultures expressing P2X7R-EGFP without (a) or with (b) IL-1β neutralization. Top
panels: green, P2X7R-EGFP, red, isolectin GS-IB4, blue, DAPI nuclear stain. Bottom panels: green, P2X7R-EGFP, blue, DAPI nuclear stain. Scale bars,
20 μm. c Primary hippocampal cultures expressing P2X7R-EGFP with caspase 1 inhibited (caspase 1−) (n = 40) showed a decrease in total number
of cells (DAPI positive) compared to the P2X7R-EGFP-expressing control (caspase 1+) (n = 40) cultures with no caspase 1 inhibition. d The number
of transfected cells expressing P2X7R-EGFP was smaller in cultures where caspase 1 was inhibited (caspase 1–) (n = 40) compared to the controls
(caspase 1+) (n = 40) with no inhibition of caspase 1. e The absolute number of microglia per imaging field was decreased in the P2X7R-EGFP-
expressing cultures with caspase 1 inhibited (caspase 1−) (n = 40) compared to the controls (caspase 1+) (n = 40). f Primary hippocampal cultures
expressing P2X7R-EGFP with IL-1β activity neutralized (IL-1β−) with the aid of a neutralizing antibody (n = 40) showed a decrease in the total
number of cells (DAPI positive) compared to the P2X7R-EGFP-expressing control (IL-1β+) (n = 40) cultures with no IL-1β neutralization. g As a
proportion of the total microglial pool (identified by isolectin GS-IB4 and DAPI nuclear counter-staining) less activated microglia were evident in
cultures expressing P2X7R-EGFP (n = 40) with the activity of IL-1β neutralized (IL-1β–) compared to the controls with no neutralization (IL-1β+) (n = 40).
h The absolute number of microglia per imaging field was decreased in the P2X7R-EGFP-expressing cultures with IL-1β neutralization (IL-1β−) (n = 40)
compared to the controls (IL-1β+) (n = 40). Imaging field dimension, 230 × 230 μm. *p < 0.05, Student’s t test
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Conclusions
In summary, the studies in this research showed that the
release of IL-1β, while dependent on P2X7R function,
requires P2X7R pore activity and is independent of cy-
tolysis. Our results support a model where up-regulation
of P2X7R and stimulation of pore activity leads to
microglial activation and subsequent release of IL-1β
through lysosomal exocytosis. This cytokine can poten-
tially maintain or accelerate the trophic responses in
microglia, with consequent deleterious cycles of neuro-
inflammation and neurodegeneration. There is evidence
that polymorphisms in P2X7R that are associated with a
loss or reduction of P2X7R function are associated with
a decreased sensitivity to inflammation [9, 74]. Given the
highly documented role of IL-1β in many neuropatho-
logical scenarios, our results suggest that specific ma-
nipulation of P2X7R pore could be utilized to reduce the
degree of microglial activation, and this therapeutic
strategy holds promise in the setting of Alzheimer’s and
other neurodegenerative diseases, as well as neoplastic con-
ditions where effective interventions are currently lacking.
Additional file
Additional file 1: Prior to the commencement of the video, activated
microglia expressing P2X7R-EGFP were loaded with FM1-43. When the
cells were then stimulated with BzATP (100μM) (at the commencement
of the video), vesicles of ~200μm diameter appeared on the surface of
the cell with subsequent ‘release events’ (seen in the video as fusion of
green ‘beaded’ structures to the surface membrane). Exocytosis was
relatively fast with application of the agonist, reaching its maximum by
mid-section of the video. The entire duration (real-time) lapsed during
the video is 24.75 minutes. In total 100 images (1 image every 15
seconds) were captured for this experiment, and played at approximately
10 images per second. (MOV 6.25 mb)
Abbreviations
BzATP, 2′3′-O-(4-benzoylbenzoyl)-ATP (agonist of P2X7R); FM1-43, fixable
fluorescent probe used to study vesicular recycling; IL-1β, interleukin-1beta
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